SAD/MAD of MTP-131
Research type
Research Study
Full title
A Two-Part Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MTP-131 and Multiple Ascending Doses of MTP-131 Administered Subcutaneously to Healthy Volunteers
IRAS ID
163616
Contact name
Stuart Mair
Contact email
Sponsor organisation
Stealth Peptides Inc
Eudract number
2014-003685-24
Duration of Study in the UK
0 years, 5 months, 6 days
Research summary
MTP-131 is being developed for the treatment of disease in which oxidative stress is considered a likely pathologic mechanism. Diseases that have been linked to oxidative stress, such as heart failure, mitochondrial muscle dysfunction and various ophthalmic diseases, are being considered as possible targets for treatment by MTP-131.
REC name
Wales REC 1
REC reference
14/WA/1132
Date of REC Opinion
14 Oct 2014
REC opinion
Further Information Favourable Opinion